Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony T Reder

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Multiple Sclerosis and Related Disorders|August 13, 2015
First-dose effects of fingolimod: Pooled safety data from three phase 3 studiesJohn P DiMarco, Paul O'Connor, Jeffrey A Cohen, et al.
Clinical Therapeutics|October 8, 2009
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational studyGeorge C Ebers, Anthony T Reder, Anthony Traboulsee, et al.
JAMA Ophthalmology|January 12, 2013
Cystoid macular edema associated with fingolimod use for multiple sclerosisArmin R Afshar, Joshua K Fernandes, Ravi D Patel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2004
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosisA John Petkau, Richard A White, George C Ebers, et al.
International Journal of Cell Biology|January 29, 2011
Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein SignalingTiffany Tran, Pedro Paz, Sharlene Velichko, et al.
Multiple Sclerosis and Related Disorders|April 21, 2021
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosisAnthony T Reder, Nancy Arndt, Cortnee Roman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 24, 2011
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosisDouglas S Goodin, Anthony Traboulsee, Volker Knappertz, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 13, 2008
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expressionAnthony T Reder, Sharlene Velichko, Ken D Yamaguchi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 26, 2021
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosisBruce Ac Cree, Jeffrey A Cohen, Anthony T Reder, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|August 13, 2015
First-dose effects of fingolimod: Pooled safety data from three phase 3 studiesJohn P DiMarco, Paul O'Connor, Jeffrey A Cohen, et al.
Clinical Therapeutics|October 8, 2009
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational studyGeorge C Ebers, Anthony T Reder, Anthony Traboulsee, et al.
JAMA Ophthalmology|January 12, 2013
Cystoid macular edema associated with fingolimod use for multiple sclerosisArmin R Afshar, Joshua K Fernandes, Ravi D Patel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2004
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosisA John Petkau, Richard A White, George C Ebers, et al.
International Journal of Cell Biology|January 29, 2011
Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein SignalingTiffany Tran, Pedro Paz, Sharlene Velichko, et al.
Multiple Sclerosis and Related Disorders|April 21, 2021
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosisAnthony T Reder, Nancy Arndt, Cortnee Roman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 24, 2011
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosisDouglas S Goodin, Anthony Traboulsee, Volker Knappertz, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 13, 2008
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expressionAnthony T Reder, Sharlene Velichko, Ken D Yamaguchi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 26, 2021
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosisBruce Ac Cree, Jeffrey A Cohen, Anthony T Reder, et al.
Pageof 9